Company Overview
Snapshot
Founded in December 2021 by Or Shoval, Michal Tsur, and Shahar Shelly, Remepy operates with 51–200 employees. The company has raised $25 million across 4 funding rounds from 10 investors. In April 2026, Remepy announced a collaboration with Merck KGaA to advance hybrid drugs across various therapeutic areas.
Business overview
Remepy is a Health Tech & Life Sciences company pioneering hybrid drugs and redefining combination therapy to bring personalized care to patients. The company's core technology involves Digital Molecules, which are mobile applications designed for hybrid drug experiences, each containing a unique digital treatment protocol. These Digital Molecules include digitized, standardized, evidence-based interventions aimed at enhancing brain plasticity and connectivity, balancing the immune system, and driving behavioral changes. Remepy addresses disease endpoints, side effects, and comorbidities, partnering with pharmaceutical companies to combine its Digital Molecules with traditional drug components. The company operates in the Digital Healthcare and Pharma & Medical Biotechnology sectors, focusing on drug discovery and development, and serves the United States market.
Strategic signal
In May 2026, Remepy reported strong Phase IIa clinical trial results for Hybridopa, a novel Hybrid Drug designed for Parkinson's disease. This successful clinical outcome provides significant validation for Remepy's hybrid drug platform, signaling to investors and the pharmaceutical industry the potential for a new class of therapeutics that combine digital interventions with traditional drug components, particularly in neurodegenerative diseases.
Log in to access full profile ›Company Intelligence Q&A
- What significant clinical trial results did Remepy announce recently?
- In May 2026, Remepy announced strong Phase IIa clinical trial results for Hybridopa, its Hybrid Drug developed for Parkinson's disease.
- What strategic collaboration did Remepy form in April 2026?
- In April 2026, Remepy announced a collaboration with Merck KGaA, Darmstadt, Germany, to advance hybrid drugs across various therapeutic areas, including rare tumor programs.
- What was the outcome of Remepy's mobile app study in June 2025?
- In June 2025, Remepy's mobile app was shown to rewire the brain, modulate the immune system, and improve mood in adults with subjective cognitive decline.
- When did Remepy raise its Seed funding round and who were the lead investors?
- In May 2024, Remepy raised a Seed funding round. NFX Capital was a lead investor in this round.
- When did former Israeli Prime Minister Naftali Bennett join Remepy's board?
- In February 2024, former Israeli Prime Minister Naftali Bennett joined Remepy's board to support its hybrid drug endeavors.